CHESTER, N.Y.--(BUSINESS WIRE)--Innovative Health Sciences, LLC (“IHS” or the “Company”) management announced today that IHS has received FDA clearance for its Insignis™ Subcutaneous Needle Sets. This ...

KORU Medical Systems, Inc. KRMD has made a strategic move in its pursuit of expanding its footprint in the realm of large-volume subcutaneous infusion. The company announced a collaboration with a ...

SAN DIEGO, Dec. 30, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (HALO) (Halozyme) today announced that Takeda received regulatory approval for HYQVIA ® [Immune Globulin Infusion 10% (Human) with ...

OSAKA, Japan & CAMBRIDGE, Mass., December 27, 2024--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA ...

MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on development, manufacturing, and ...

Learn how to self-administer SCIg at home for primary immunodeficiency. Tips on preparation, reducing pain, managing ...

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on ...

MAHWAH, N.J.--(BUSINESS WIRE)-- KORU Medical Systems, Inc. (KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and ...

Subcutaneous amivantamab offers a convenient alternative to IV administration for EGFR-mutated NSCLC, reducing infusion-related reactions and administration time. The PALOMA-3 trial confirmed ...

Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant ...